RESEARCH MONOGRAPH · KDC-MN-075

Agmatine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

Endogenous polyamine that punches above its weight on NMDA, imidazoline, and nitric oxide signaling

Agmatine is honestly slept-on. It's an endogenous polyamine derived from arginine decarboxylation, so technically your CNS already makes it (the ADC enzyme is present in mammalian brain at low levels, though the bulk of mammalian agmatine probably comes from gut microbiome arginine metabolism). And its target profile is unusually broad in a useful way.

Mechanism-wise: imidazoline I1 and I2 receptor agonist, alpha-2 adrenergic modulator, NMDA receptor antagonist at the polyamine site, nitric oxide synthase inhibitor (mostly nNOS and iNOS), and a noncompetitive NOS inhibitor at higher concentrations. The Reis and Regunathan group at Cornell did the foundational work in the 90s identifying it as the endogenous I1 ligand, and the field has been slowly building since.

What we like: the analgesic and neuroprotective preclinical literature is genuinely consistent across labs, which is rare. Gilad and colleagues have shown reproducible effects in neuropathic pain models, the NMDA polyamine-site antagonism is interesting for opioid tolerance reversal work, and the I1 imidazoline activity makes it a useful tool compound for studying that underexplored receptor system. Plus its an endogenous compound at micromolar plasma concentrations, so the toxicology floor is reassuring.

What we dont like: human clinical evidence is thin. Theres a small open-label pain study from a Polish group and some pilot work in fibromyalgia, but nothing convincing at scale. The oral bioavailability question is also annoying because agmatine is a polar small molecule that doesnt cross BBB efficiently, so peripheral vs. central effects are partially disentangled and partially not. The bulk of the preclinical work uses parenteral dosing.

Sourcing is mostly fine. Agmatine sulfate is the common form, simple to synthesize from arginine, HPLC pure is widely available at gram scale. Stability is decent if you keep it dry.

For research on imidazoline receptors, NMDA polyamine-site modulation, or opioid tolerance pharmacology, agmatine is genuinely valuable and underused. The endogenous-compound angle plus the broad target profile makes it interesting in a way the supplement scene doesnt really capture.

Evidence: 45
Mechanism: 75
Reliability: 65
Safety: 80
Sourcing: 78
Value: 75
Signal: 68
Staying power: 65

Plain-language summary Intrigue 55 / 100

Agmatine is a naturally occurring small molecule made in the body from arginine. It modulates several systems including NMDA receptors, nitric oxide, and imidazoline receptors. Used as a supplement for nerve pain and mood. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous polyamine / NMDA modulator

An endogenous decarboxylated arginine derivative with NMDA receptor antagonism, alpha-2 adrenergic agonism, and imidazoline receptor binding.

Abstract

Agmatine ((4-aminobutyl)guanidine; CAS 306-60-5; molecular formula C5H14N4; molecular weight 130.19) is an endogenous polyamine produced by decarboxylation of arginine. The compound is present in plasma and brain at micromolar concentrations and acts at multiple receptor systems: NMDA receptor antagonism (at the polyamine site), alpha-2 adrenergic receptor agonism, imidazoline I1 and I2 receptor binding, and modest opioid receptor effects. Agmatine has been investigated as adjunct therapy for opioid withdrawal, neuropathic pain, depression, and cognitive enhancement. The compound is sold as a dietary supplement in the United States. Pharmacokinetics: oral bioavailability moderate; plasma half-life of exogenous agmatine approximately 2 hours; the compound is hepatically metabolized by agmatinase to putrescine. Reported research dose ranges in the literature are described in the source monograph.

Mechanism of action

NMDA polyamine site antagonism, alpha-2 adrenergic agonism, imidazoline I1/I2 binding, modest opioid effects.

Reported research dose ranges

1 to 3 grams (reported research dose range).

References

Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 2000.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-075

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Agmatine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs